Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial
出版年份 2013 全文链接
标题
Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial
作者
关键词
-
出版物
Journal of Diabetes Investigation
Volume 4, Issue 6, Pages 605-612
出版商
Wiley
发表日期
2013-06-03
DOI
10.1111/jdi.12102
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
- (2013) L. Meneghini et al. DIABETES CARE
- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control
- (2013) Helena Rodbard et al. Endocrine Practice
- Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
- (2012) B. Zinman et al. DIABETES CARE
- Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
- (2012) R. E. Ratner et al. DIABETES OBESITY & METABOLISM
- Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Alan J Garber et al. LANCET
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Simon Heller et al. LANCET
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- (2012) Ib Jonassen et al. PHARMACEUTICAL RESEARCH
- Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine
- (2011) K. I. Birkeland et al. DIABETES CARE
- The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management
- (2011) Meryl Brod et al. VALUE IN HEALTH
- Insulin Therapy for Type 2 Diabetes
- (2009) S. G. Swinnen et al. DIABETES CARE
- Good glycaemic control: an international perspective on bridging the gap between theory and practice in type 2 diabetes
- (2008) E. S. Kilpatrick et al. CURRENT MEDICAL RESEARCH AND OPINION
- How hypoglycaemia can affect the life of a person with diabetes
- (2007) Brian M. Frier DIABETES-METABOLISM RESEARCH AND REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started